Ingredient or product comparison
GHK-Cu for Hair Regrowth Research: Comparison of Hair Loss Treatments
GHK-Cu (topical) Copper-dependent collagen synthesis, angiogenesis, TGF-β modulation Small-scale human trials (N=23–30), no FDA approval 5.9% mean hair density increase at 12 weeks (Pickart 2007) Limited direct data. Suggested by follicle diameter increase Mec
This source-based comparison does not add ratings or recommend a winner.
- GHK-Cu (topical)
- Copper-dependent collagen synthesis, angiogenesis, TGF-β modulation
- Small-scale human trials (N=23–30), no FDA approval
- 5.9% mean hair density increase at 12 weeks (Pickart 2007)
- Limited direct data. Suggested by follicle diameter increase
- Mechanistically promising but lacks large-scale validation; no head-to-head trials vs minoxidil
- Minoxidil (5%)
- Potassium channel opener, VEGF upregulation, anagen phase extension
- FDA-approved (1988), dozens of RCTs
- 60–70% responders (≥10% density increase at 16 weeks)
- Yes. Documented in trichoscopy studies
- Gold standard topical; proven efficacy but requires continuous use
- Finasteride (oral 1mg)
- 5-alpha reductase inhibitor, reduces DHT conversion
- FDA-approved (1997), extensive RCT data
- 65–80% halt progression, 48% regrowth at 12 months
- Yes. Reverses DHT-driven miniaturisation
- Most effective oral treatment for androgenetic alopecia in men; sexual side effects in 1–2%
- PRP (platelet-rich plasma)
- Growth factor delivery, stem cell activation
- Multiple RCTs but high variability in preparation protocols
- 30–60% improvement (highly protocol-dependent)
- Suggested by histological studies, inconsistent
- Expensive, requires injections every 4–6 weeks; results vary by platelet concentration and spin protocol
- Microneedling alone
- Wound healing response, collagen induction, improved topical penetration
- Moderate clinical evidence (small RCTs)
- 20–40% improvement when combined with minoxidil
- Limited standalone data
- Best used as an adjunct to increase delivery of active compounds